159 related articles for article (PubMed ID: 25039982)
1. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
[TBL] [Abstract][Full Text] [Related]
2. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P
Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471
[TBL] [Abstract][Full Text] [Related]
3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
4. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
5. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
6. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
[TBL] [Abstract][Full Text] [Related]
7. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
8. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
[TBL] [Abstract][Full Text] [Related]
9. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
Song Z; Wang X; Zheng Y; Su H; Zhang Y
Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
[TBL] [Abstract][Full Text] [Related]
12. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma.
Mesteri I; Schoppmann SF; Preusser M; Birner P
Eur J Cancer; 2014 May; 50(7):1354-60. PubMed ID: 24565853
[TBL] [Abstract][Full Text] [Related]
14. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
15. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Schildhaus HU; Schultheis AM; Rüschoff J; Binot E; Merkelbach-Bruse S; Fassunke J; Schulte W; Ko YD; Schlesinger A; Bos M; Gardizi M; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Hekmat K; Frank KF; Reiser M; Schulz H; Krüger S; Stoelben E; Zander T; Wolf J; Buettner R
Clin Cancer Res; 2015 Feb; 21(4):907-15. PubMed ID: 25492085
[TBL] [Abstract][Full Text] [Related]
16. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
17. Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
Zhang N; Xie F; Gao W; Yu S; Qiu L; Lin W; Sun Y; Jia T
Mol Med Rep; 2015 Apr; 11(4):2797-804. PubMed ID: 25504327
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]